SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.24

• SELLAS Life Sciences press release (NASDAQ:SLS): FY GAAP EPS of -$1.34 misses by $0.24.
• As of December 31, 2023, cash and cash equivalents totaled approximately $2.5 million. On January 8, 2024, the Company received gross proceeds of $9.0 million from a public offering.
• On March 19, 2024, the Company received gross proceeds of $20.0 million from a registered direct offering priced at-the-market under Nasdaq rules.

More on SELLAS Life Sciences

• SELLAS Life Sciences looks to raise $20M in a direct offering
• Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment
• Seeking Alpha’s Quant Rating on SELLAS Life Sciences
• Historical earnings data for SELLAS Life Sciences
• Financial information for SELLAS Life Sciences